Serum interα-trypsin inhibitor heavy chain H4 may be an anti-inflammatory marker reflecting disease risk, activity and treatment outcome of ankylosing spondylitis

References

• Mauro D, Thomas R, Guggino G, et al. Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat Rev Rheumatol. 2021;17(7):387–404. doi: 10.1038/s41584-021-00625-y.
   PubMed Web of Science ®Google Scholar
• Voruganti A, Bowness P. New developments in our understanding of ankylosing spondylitis pathogenesis. Immunology. 2020;161(2):94–102. doi: 10.1111/imm.13242.
   PubMed Web of Science ®Google Scholar
• Crossfield SSR, Marzo-Ortega H, Kingsbury SR, et al. Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. RMD Open. 2021;7(3):e001888. doi: 10.1136/rmdopen-2021-001888.
   PubMed Web of Science ®Google Scholar
• Klavdianou K, Tsiami S, Baraliakos X. New developments in ankylosing spondylitis-status in 2021. Rheumatology (Oxford). 2021;60(6):vi29–vi37. doi: 10.1093/rheumatology/keab523.
   PubMedGoogle Scholar
• Hu X, Chen J, Tang W, et al. Effects of exercise programmes on pain, disease activity and function in ankylosing spondylitis: a meta-analysis of randomized controlled trials. Eur J Clin Invest. 2020;50(12):e13352. doi: 10.1111/eci.13352.
   PubMed Web of Science ®Google Scholar
• Garcia-Montoya L, Gul H, Emery P. Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Res. 2018;7:1512. doi: 10.12688/f1000research.14956.1.
   Google Scholar
• Korotaeva T, Dina O, Holdsworth E, et al. Investigating diagnosis, treatment, and burden of disease in patients with ankylosing spondylitis in Central Eastern Europe and the United States: a real-world study. Clin Rheumatol. 2021;40(12):4915–4926. doi: 10.1007/s10067-021-05864-8.
   PubMed Web of Science ®Google Scholar
• Komel Pimenta PR, Ribeiro da Silva MR, Ribeiro Dos Santos JB, et al. Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study. J Comp Eff Res. 2021;10(6):509–517. doi: 10.2217/cer-2020-0275.
   PubMed Web of Science ®Google Scholar
• Lorenzin M, Ortolan A, Frallonardo P, et al. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord. 2015;16(1):166. doi: 10.1186/s12891-015-0620-4.
   PubMedGoogle Scholar
• Pihl R, Jensen RK, Poulsen EC, et al. ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism. Sci Adv. 2021;7(2):eaba7381. doi: 10.1126/sciadv.aba7381.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Ezura Y, Emi M, et al. Hypercholesterolemia associated with splice-junction variation of inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) gene. J Hum Genet. 2004;49(1):24–28. doi: 10.1007/s10038-003-0101-8.
   PubMed Web of Science ®Google Scholar
• Ma Y, Li R, Wang J, et al. ITIH4, as an inflammation biomarker, mainly increases in bacterial bloodstream infection. Cytokine. 2021;138:155377. doi: 10.1016/j.cyto.2020.155377.
   PubMed Web of Science ®Google Scholar
• Zou YC, Yan LM, Gao YP, et al. miR-21 may act as a potential mediator between inflammation and abnormal bone formation in ankylosing spondylitis based on TNF-alpha Concentration-Dependent manner through the JAK2/STAT3 pathway. Dose Response. 2020;18(1):1559325819901239. doi: 10.1177/1559325819901239.
   Web of Science ®Google Scholar
• Stober VP, Lim YP, Opal S, et al. Inter-alpha-inhibitor ameliorates endothelial inflammation in sepsis. Lung. 2019;197(3):361–369. doi: 10.1007/s00408-019-00228-1.
   PubMed Web of Science ®Google Scholar
• Li J, Chen Z, Liao H, et al. Anti-Osteogenic effect of danshensu in ankylosing spondylitis: an in vitro study based on integrated network pharmacology. Front Pharmacol. 2021;12:772190. doi: 10.3389/fphar.2021.772190.
   PubMed Web of Science ®Google Scholar
• Wen N, Zhao N, Xu H, et al. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment. Ir J Med Sci. 2022;191(5):2105–2111. doi: 10.1007/s11845-021-02837-3.
   PubMed Web of Science ®Google Scholar
• He K, He S, Su M. Inter-alpha-trypsin inhibitor heavy chain 4: a serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis. J Clin Lab Anal. 2022;36:e24231.
   PubMed Web of Science ®Google Scholar
• Braun J, van den Berg R, Baraliakos X, et al. 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896–904. doi: 10.1136/ard.2011.151027.
   PubMed Web of Science ®Google Scholar
• Dou B, Ma F, Jiang Z, et al. Blood HDAC4 variation links with disease activity and response to tumor necrosis factor inhibitor and regulates CD4+ T cell differentiation in ankylosing spondylitis. Front Med (Lausanne). 2022;9:875341. doi: 10.3389/fmed.2022.875341.
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of SpondyloArthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(2):ii1–44. doi: 10.1136/ard.2008.104018.
   PubMedGoogle Scholar
• Jiang J, Zhan X, Qu H, et al. Upregulated of ANXA3, SORL1, and neutrophils may be key factors in the progressionof ankylosing spondylitis. Front Immunol. 2022;13:861459. doi: 10.3389/fimmu.2022.861459.
   PubMed Web of Science ®Google Scholar
• Osada A, Matsumoto I, Mikami N, et al. Citrullinated inter-alpha-trypsin inhibitor heavy chain 4 in arthritic joints and its potential effect in the neutrophil migration. Clin Exp Immunol. 2021;203(3):385–399. doi: 10.1111/cei.13556.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Suzuki M, Tanaka Y, et al. A kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling Cascade. J Biol Chem. 2003;278(10):7790–7799. doi: 10.1074/jbc.M210407200.
   PubMed Web of Science ®Google Scholar
• Dong Q, Jie Y, Ma J, et al. Renal tubular cell death and inflammation response are regulated by the MAPK-ERK-CREB signaling pathway under hypoxia-reoxygenation injury. J Recept Signal Transduct Res. 2019;39(5-6):383–391. doi: 10.1080/10799893.2019.1698050.
   PubMed Web of Science ®Google Scholar
• Lord MS, Melrose J, Day AJ, et al. The inter-alpha-Trypsin inhibitor family: versatile molecules in biology and pathology. J Histochem Cytochem. 2020;68(12):907–927. doi: 10.1369/0022155420940067.
   PubMed Web of Science ®Google Scholar
• Ni K, Gill A, Tseng V, et al. Rapid clearance of heavy chain-modified hyaluronan during resolving acute lung injury. Respir Res. 2018;19(1):107. doi: 10.1186/s12931-018-0812-1.
   PubMedGoogle Scholar
• Jo S, Won EJ, Kim MJ, et al. STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis. Rheumatology (Oxford). 2021;60(8):3923–3935. doi: 10.1093/rheumatology/keaa846.
   PubMed Web of Science ®Google Scholar
• Park JW, Kim MJ, Lee JS, et al. Impact of tumor necrosis factor inhibitor versus nonsteroidal antiinflammatory drug treatment on radiographic progression in early ankylosing spondylitis: its relationship to inflammation control during treatment. Arthritis Rheumatol. 2019;71(1):82–90. doi: 10.1002/art.40661.
   PubMed Web of Science ®Google Scholar
• de Toledo RA, Grizzo FMF, Fernandes V, et al. Maintained activity in ankylosing spondylitis patients treated with TNFi and/or NSAID for at least 12 weeks: a cross-sectional study in Brazil. Adv Rheumatol. 2022;62(1):38. doi: 10.1186/s42358-022-00270-3.
   PubMedGoogle Scholar
• Ma L, Gong H, Zhu H, et al. A novel small-molecule tumor necrosis factor alpha inhibitor attenuates inflammation in a hepatitis mouse model. J Biol Chem. 2014;289(18):12457–12466. doi: 10.1074/jbc.M113.521708.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen Y, Liu T, et al. Impact of tumor necrosis factor alpha inhibitors on MRI inflammation in axial spondyloarthritis assessed by spondyloarthritis research consortium Canada score: a meta-analysis. PLoS One. 2020;15(12):e0244788. doi: 10.1371/journal.pone.0244788.
   PubMed Web of Science ®Google Scholar